CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 23 pages
Summary of three economic analyses on the use of PCVs among 50-64 year old adults in the United States Andrew J. Leidner, Sofia Bletnitsky Applied Research, Implementation Science and Evaluation (ARISE) Branch Immunization Services Division (ISD) NCIRD ACIP Meeting October 23, 2024NCIRD/ISD/ARISE Disclaimer: Views and opinions expressed in this presentation are the authors and do not necessarily represent the views and opinions of the Centers for Disease Control and Prevention .1 •This…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 67 pages
Summary of Work Group Interpretation of EtR and Policy Options PCV Use in Adults aged ≥50 years October 23, 2024 Miwako Kobayashi, MD, MPHNational Center for Immunization and Respiratory Diseases 1 PICO for WG discussion through October 2024 CMC=chronic medical conditions (i.e., alcoholism; chronic heart disease, including congestive heart failure and cardiomyopath ies; chronic liver disease; chronic lung disease, including chronic obstructive pulmonary disease, emphysema, and asthma;…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 8 pages
National Center for Immunization & Respiratory Diseases Influenza Work Group —Introduction Dr. Jamie Loehr (Work Group Chair) Advisory Committee on Immunization Practices October 23, 2024 Influenza Work Group ACIP Members •Jamie Loehr (Chair) •Robert Schechter •Albert Shaw •Keipp Talbot Ex Officio •Timothy Brennan (FDA) •Uzo Chukwuma (IHS) •Michael Ison (NIH) •Cynthia Nolletti (FDA) •Jo Resnick (FDA) •Chris Roberts (NIH)Liaison Representatives and Consultants •Robert Atmar •Kevin Ault •Ed…
CDC ACIP — Vaccine Advisory Committee
· Acip
/ Slides
· 46 pages
National Center for Immunization & Respiratory Diseases 2023 –24 End of Season Influenza Vaccine Effectiveness – United States Sascha Ellington, PhD, MSPH Influenza Division U.S. Centers for Disease Control and Prevention 2023 –2024 Influenza Season •A(H1N1)pdm09 predominant •Lower levels of A(H3N2) and B/Victoria circulation •Peak activity 2023 week 52 •Vaccines were quadrivalent and included A(H1N1)pdm09, A(H3N2), and B components H1N1 H3N2B 3CDC Influenza Vaccine Effectiveness…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Karen N. Allen · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $453,520 — Complex glycoconjugates play a pivotal role in bacterial survival, colonization, and virulence, and contribute to the interactions between symbiotic and pathogenic bacteria and their human hosts. Assembly of these macromolecules is initiated on the cytoplasmic face of cell membranes, catalyzed by po…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Briana Shimada · UNIVERSITY OF HAWAII AT MANOA · 2024 · $155,398 — This proposal will investigate the role of the selenium (Se)-recycling enzyme, selenocysteine lyase (Scly), in combination with high fructose and dietary Se deficiency impacts cardiac function. Se deficiency has been associated with an increased risk of cardiometabolic disorders including type 2 …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
GABOR J TIGYI · UNIVERSITY OF MARYLAND BALTIMORE · 2024 · $286,130 — The US population at large, and particularly military personnel and first responders, are at risk of radiation expo-sure due to the explosion of a nuclear device, a nuclear reactor accident, and the threat of radiation terrorism. There is no radiation medical countermeasure (RCM) drug approved by t…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Huan Xie · TEXAS SOUTHERN UNIVERSITY · 2024 · $342,330 — PROJECT SUMMARY Prostate cancer (PCa) is the second leading cause of cancer death in the United States among men and it is more common in African American males. Despite initial good responses to androgen deprivation or anti- androgen drugs, tumors invariably recur and develop into lethal castration…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Irina A. Kirpich · UNIVERSITY OF LOUISVILLE · 2024 · $245,405 — Alcoholic liver disease (ALD) is a major and increasing health problem in the US (especially in Kentucky) and worldwide. In spite of the magnitude of this problem, there is no FDA-approved therapy for any stage of ALD. In addition, the mechanisms and regulators of the disease progression and severit…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Jianxin You · UNIVERSITY OF PENNSYLVANIA · 2024 · $410,686 — Project Abstract Merkel cell carcinoma (MCC) is one of the most aggressive skin cancers. Clonal integration of Merkel cell polyomavirus (MCPyV) genome into the host DNA has been observed in ~80% of MCCs, and represents a key causal factor for MCC development. LT and sT encoded by MCPyV genome have b…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Sheng Tong · UNIVERSITY OF KENTUCKY · 2024 · $191,250 — Summary CRISPR/cas9 gene editing has shown great promise for the treatment of genetic hematologic disorders including sickle cell disease and β-thalassemia. Current therapeutic strategies are primarily focused on ex vivo gene editing of autologous patient-derived hematopoietic stem/progenitor cells …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Maegan M Weltzin · UNIVERSITY OF ALASKA FAIRBANKS · 2024 · $77,500 — ABSTRACT. In the U.S., major depressive disorder (MDD) is the most common mental disorder, with depression prevalence approaching 20% among adolescents and young adults. Current pharmacological treatments are unsatisfactory in that 33-55% of people suffering from MDD are non-responsive. MDD is assoc…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
THOMAS D. SCHMITTGEN · UNIVERSITY OF FLORIDA · 2024 · $203,188 — Project Summary Pancreatic ductal adenocarcinoma (PDAC) is currently the third most lethal cancer in the United States. It is currently the third leading of cancer-related deaths in the United States and by the end of this decade, pancreatic cancer is predicted to pass colorectal cancer, making it t…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Qingxin Mu · UNIVERSITY OF WASHINGTON · 2024 · $168,413 — Project Description Triple negative breast cancer (TNBC) is the most challenging subtype to treat among all breast cancer cases due to lack of cell surface receptors. Patients with metastatic TNBC have median overall survival of only 13.3 months with treatment. Newly approved immune checkpoint inhi…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Admire Dube · STELLENBOSCH UNIVERSITY · 2024 · $303,416 — SUMMARY Tuberculosis remains a major global public health threat. Although relatively effective drug regimens are available, treatment failure remains a major roadblock to tuberculosis control. This is in part due to a high incidence of drug-resistant Mycobacterium tuberculosis (Mtb) strains, as wel…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Jian-Xing Jay Ma · VIRGINIA COMMONWEALTH UNIVERSITY · 2024 · $538,028 — PROJECT SUMMARY Diabetic retinopathy (DR) is the most common cause of severe vision loss in the working-age population in the world. However, clinical studies have shown that approximately 40% DR patients do not adequately respond to anti-VEGF drugs. There is no drug treatment for those 40% DR pati…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Amaia Lujambio · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · 2024 · $589,164 — Chronic liver disease and its common sequela cirrhosis, are growing public health concerns, and major risk factors for the development of hepatocellular cancer (HCC). HCC incidence and mortality is growing in the USA. Optimal medical therapies for HCC are lacking. FDA approved agents are modestly ef…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Ju-Tao Guo · BARUCH S. BLUMBERG INSTITUTE · 2024 · $240,000 — Abstract This R21/R33 application is to develop our proprietary chemically ligated guide RNA (lgRNA)-based CRISPR/Cas9 gene editing technology for therapeutic elimination of hepatitis B virus (HBV) covalently closed circular DNA (cccDNA) and cure of chronic hepatitis B (CHB). Prior studies have alre…
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Gregory A. Newby · JOHNS HOPKINS UNIVERSITY · 2024 · $249,000 — PROJECT SUMMARY Genetic diseases impact over 1 in 50 newborns worldwide and yet there are no approved therapies capable of correcting the underlying genetic defects. As a result, most patients continue to suffer throughout their life and require frequent interventions to ameliorate symptoms. I aim …
NIH Pandemic-Era Grants
· Pandemic Era Grants
/ 2024
Joelle Payne Straehla · DANA-FARBER CANCER INST · 2024 · $1 — PROJECT SUMMARY Nanoparticle-based therapies have many potential advantages for treating cancer, but there are currently no clinical biomarkers to predict which patients are most likely to benefit from nanotherapeutics over conventional anticancer agents. To improve the efficacy of nanoparticles for…